Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary
(two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple …

The introduction of a third‐dose vaccination along with new variants of concern raises
questions regarding serology and T‐cell responses in patients with multiple sclerosis …

Importance B-cell–depleting therapies may affect the development of a protective immune
response following vaccination. Understanding the ability to develop vaccine-specific …

Objective To compare “hybrid immunity”(prior COVID‐19 infection plus vaccination) and post‐
vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying …

Background Patients with multiple sclerosis receiving ocrelizumab-treatment are in
desperate need of a protection against SARS-CoV-2 infection. Methods In this study …

Objectives Several concerns regard the immunogenicity of SARS-CoV-2 vaccines in people
with multiple sclerosis (pwMS), since the majority of them is treated with immunomodulating …

Background Our study investigated the rate of breakthrough SARS-CoV-2 infection and
clinical outcomes in a cohort of multiple sclerosis (MS) patients who were treated with the …

Objective The objective of this study was to determine the impact of multiple sclerosis (MS)
disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity …

Background Vaccination has proven to be effective in preventing SARS-CoV-2 transmission
and severe disease courses. However, immunocompromised patients have not been …

Early reports prior to availability of vaccinations show that treatment with anti-CD20
monoclonal antibodies (eg, rituximab, ocrelizumab) in multiple sclerosis (MS) patients is …